Journal of Pharmacy And Bioallied Sciences
Journal of Pharmacy And Bioallied Sciences Login  | Users Online: 1425  Print this pageEmail this pageSmall font sizeDefault font sizeIncrease font size 
    Home | About us | Editorial board | Search | Ahead of print | Current Issue | Past Issues | Instructions | Online submission




 
 Table of Contents  
LETTER
Year : 2013  |  Volume : 5  |  Issue : 3  |  Page : 242-243  

Pleiotropy of chemically modified tetracycline in periodontitis


Department of Periodontology, Institute of Dental Sciences, Bareilly, Uttar Pradesh, India

Date of Web Publication23-Aug-2013

Correspondence Address:
Ashish Agarwal
Department of Periodontology, Institute of Dental Sciences, Bareilly, Uttar Pradesh
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/0975-7406.116831

Rights and Permissions

How to cite this article:
Agarwal A. Pleiotropy of chemically modified tetracycline in periodontitis. J Pharm Bioall Sci 2013;5:242-3

How to cite this URL:
Agarwal A. Pleiotropy of chemically modified tetracycline in periodontitis. J Pharm Bioall Sci [serial online] 2013 [cited 2019 Oct 22];5:242-3. Available from: http://www.jpbsonline.org/text.asp?2013/5/3/242/116831

Sir,

The current layout for the biological domain map of chronic periodontitis indicates that the bacterial challenge activates immuno-inflammatory response, due to which a complex interplay of several matrix metalloproteinases (MMPs), cytokines, and prostaglandin (PGE 2 ) activates and appear to destroy extracellular matrix material and activate bone resorption. [1] Host modulation therapy (HMT) is a strategy to reduce tissue destruction and stabilize the periodontium by modifying or downregulating destructive aspects of the host response and upregulating protective or regenerative responses is a recent and novel concept in periodontal therapy. [2] Chemically modified tetracycline (CMT), a non-antimicrobial modified tetracycline with versatile anti-inflammatory properties but potent host-modulating effects, is an excellent agent for the management of periodontitis. CMTs were produced by removing the dimethylamino group from the carbon-4 position of the A ring of the four-ringed (A, B, C, D) tetracycline structure. The resulting compound, 4-de-dimethyl amino tetracycline (CMT-1), did not have antimicrobial property, but the anti-collagenase activity was retained both in vitro and in vivo. [3] The main advantage of CMTs over the conventional tetracyclines is that long-term systemic administration does not cause gastrointestinal toxicity and higher plasma concentrations can be obtained with less frequent administration regimens.

CMTs combat to periodontitis via prevention of connective tissue breakdown through inhibition of metal-dependant MMPs, suppression of neutrophils, and inhibition of generation of arachidionic acid metabolites by blocking the phospholipase A 2 and PGE 2 synthesis, scavenging the reactive oxygen species, enhancing the attachment of fibroblasts and connective tissues to the tooth surface, and hence regenerating lost periodontium. [4] Currently, sub-antimicrobial dose doxycycline (SDD) and minocycline have been established as effective HMT. Various researches in the literature has proposed the beneficial effects of adjunctive HMT without surgery in the management of periodontist. [5] Recent studies have demonstrated superior therapeutic role of SDD in combination with access flap debridement for improvement of post-operative wound healing and periodontal health in chronic periodontitis. Other accumulating evidences revealed successful management of periodontal disease in patients with postmenopausal osteoporosis (decrease bone mass condition). Nevertheless, various biomarkers in gingival cervicular fluid (e.g., collagen telopeptide fragments) were found to reduce in subjects following SDD dosing. The field of "perioceutics," or the use of pharmacological agents, specifically developed to better manage periodontitis, is emerging to aid in the management of susceptible patients who are sub-optimally responding to the conventional therapy for periodontal disease.

 
   References Top

1.Page CR, Kornman KS. The pathogenesis of human periodontitis: An introduction. Periodontol 2000 1997;14:9-11.  Back to cited text no. 1
    
2.Golub LM, Sorsa T, Lee HM, Ciancio S, Sorbi D, Ramamurthy NS, et al. Doxycycline inhibits neutrophil (PMN)-type matrix metalloproteinases in human adult periodontitis ginigva. J Clin Periodontal 1995;22:100-9.  Back to cited text no. 2
    
3.Grenier D, Plamondon P, Sorsa T, Lee HM, McNamara T, Ramamurthy NS, et al. Inhibition of proteolytic, serpinolytic, and progelantinase-b activation activities of periodontopathogens by doxycycline and the non-antimicrobial chemically modified tetracycline derivatives. J Periodontol 2002;73:79-85.  Back to cited text no. 3
    
4.Golub LM, Lee HM, Ryan ME, Giannobile WV, Payne J, Sorsa T. Tetracycline inhibit connective tissue breakdown by multiple non-antimicrobial mechanisms. Adv Dent Res 1998;12:12-26.  Back to cited text no. 4
    
5.Honibald EN, Mathew S, Padmanaban J, Sundaram E, Ramamoorthy RD. Perioceutics: Matrix metalloproteinase inhibitor as an adjunctive therapy for inflammatory periodontal disease. J Pharm Bioallied Sci 2012;4:S417-21.  Back to cited text no. 5
    




 

Top
 
 
  Search
 
    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
    Access Statistics
    Email Alert *
    Add to My List *
* Registration required (free)  

 
  In this article
    References

 Article Access Statistics
    Viewed1364    
    Printed17    
    Emailed0    
    PDF Downloaded105    
    Comments [Add]    

Recommend this journal